Patents Assigned to VIIV Healthcare Company
  • Publication number: 20240091159
    Abstract: Methods are provided for treating or preventing human immunodeficiency virus-1 (HIV-1) or human immunodeficiency virus-2 (HIV-2) in a virologically suppressed patient in need thereof comprising switching the patient from an antiretroviral treatment regimen comprising at least three antiretroviral agents to a treatment regimen comprising only two antiretroviral agents. In one aspect the two treatment regimen consists of dolutegravir, rilpivirine and at least one pharmaceutically acceptable excipient, diluent or carrier. In another aspect of the invention, there is provided a multilayer tablet comprising dolutegravir or a pharmaceutically acceptable salt thereof and rilpivirine or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 7, 2023
    Publication date: March 21, 2024
    Applicants: ViiV Healthcare Company, Janssen Sciences Ireland Unlimited Company
    Inventors: Kenneth Churchill CAMPBELL, Urbain Alfons C. DELAET, James M. GOODRICH, Juliette Segolène GUAQUIÈRE, Thomas LAUGHERY, Dominique J. LIMET, John C. POTTAGE, Ludovic Sylvain Marc RENOU, Trevor R. SCOTT, Christian SEILER, Mary WOODWARD
  • Publication number: 20240051972
    Abstract: The invention relates to compounds of Formula (I), (Ia), (Ib), (II) or (III), salts thereof, pharmaceutical compositions thereof, as well as therapeutic methods of treatment and prevention.
    Type: Application
    Filed: August 31, 2022
    Publication date: February 15, 2024
    Applicants: GlaxoSmithKline Intellectual Property Development Limited, The University of North Carolina at Chapel Hill, ViiV Healthcare Company
    Inventors: Martha DE LA ROSA, Richard M. DUNHAM, David MARGOLIS, Vincent Wing-Fai TAI, Jun TANG
  • Publication number: 20230285307
    Abstract: The present invention relates to formulations comprising dolutegravir or a pharmaceutically acceptable salt thereof, processes for making such formulations, and the use of such formulations in the treatment of HIV infection, in particular in the treatment of HIV infection in pediatric patients.
    Type: Application
    Filed: June 23, 2021
    Publication date: September 14, 2023
    Applicant: ViiV Healthcare Company
    Inventors: Ian Paul CONN, Mark Robert DAVIES, Joanne HEAFIELD, Michael HOLTON, Neil MORTIMER
  • Publication number: 20230233470
    Abstract: The present invention relates to formulations comprising dolutegravir or a pharmaceutically acceptable salt thereof, abacavir or a pharmaceutically acceptable salt thereof and lamivudine, processes for making such formulations, and the use of such formulations in the treatment of HIV infection, in particular in the treatment of HIV infection in pediatric patients.
    Type: Application
    Filed: June 23, 2021
    Publication date: July 27, 2023
    Applicant: ViiV Healthcare Company
    Inventors: Ian Paul CONN, Mark Robert DAVIES, Jose Maria FUEYO, Joanne HEAFIELD, Trevor Martin SHREEVES
  • Publication number: 20230151049
    Abstract: The invention relates to compounds of Formula (I), salts thereof, pharmaceutical compositions thereof, as well as methods of treating or preventing HIV in subjects.
    Type: Application
    Filed: March 18, 2021
    Publication date: May 18, 2023
    Applicant: VIIV HEALTHCARE COMPANY
    Inventor: Namasimhulu B. NAIDU
  • Patent number: 11564921
    Abstract: A method of treating HIV comprising intramuscular administration once every 4 weeks or less frequently of a combination of cabotegravir or a pharmaceutically acceptable salt thereof and rilpivirine or a pharmaceutically acceptable salt thereof, including the option of discontinuing administration of a first oral anti-retroviral regimen and intramuscularly administering, once four weeks or less often said combination of cabotegravir and rilpivirine.
    Type: Grant
    Filed: July 18, 2018
    Date of Patent: January 31, 2023
    Assignees: ViiV Healthcare Company, Janssen Sciences Ireland Unlimited Company
    Inventors: Herta Crauwels, David Margolis, William R. Spreen, Andrew Spaltenstein, Peter Williams
  • Publication number: 20220411425
    Abstract: The invention relates to a compound having the structure: or a pharmaceutically acceptable salt thereof, along with pharmaceutical compositions and therapeutic methods thereof.
    Type: Application
    Filed: June 1, 2021
    Publication date: December 29, 2022
    Applicants: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED, VIIV HEALTHCARE COMPANY
    Inventors: Martha Alicia DE LA ROSA, John F. MILLER, B. Narasimhulu NAIDU, Vicente SAMANO, David TEMELKOFF, Emile Johann VELTHUISEN
  • Patent number: 11492361
    Abstract: The invention relates to compounds of Formula (I), salts thereof, combinations, pharmaceutical compositions thereof, as well as therapeutic methods of treatment and prevention.
    Type: Grant
    Filed: October 5, 2020
    Date of Patent: November 8, 2022
    Assignees: GlaxoSmithKline Intellectual Property Development Limited, The University of North Carolina at Chapel Hill, ViiV Healthcare Company
    Inventors: Richard M. Dunham, David Margolis, Vincent Wing-Fai Tai, Jun Tang
  • Publication number: 20220298160
    Abstract: The invention relates to compounds of Formulae (I)-(II), salts thereof, pharmaceutical compositions thereof, as well as methods of treating or preventing HIV in subjects.
    Type: Application
    Filed: August 28, 2020
    Publication date: September 22, 2022
    Applicants: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED, VIIV HEALTHCARE COMPANY
    Inventors: Martha Alicia DE LA ROSA, John MILLER, Lita S. SUWANDI, David TEMELKOFF, Emile Johann VELTHUISEN
  • Publication number: 20220259252
    Abstract: The invention relates to compounds of Formulae (I) and (II), salts thereof, pharmaceutical compositions thereof, as well as methods of treating or preventing HIV in subjects.
    Type: Application
    Filed: July 30, 2020
    Publication date: August 18, 2022
    Applicants: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED, VIIV HEALTHCARE COMPANY
    Inventors: John MILLER, Vicente SAMANO, David TEMELKOFF, Emile Johann VELTHUISEN
  • Publication number: 20220213121
    Abstract: Substituted 1,2,3,3a,4,5,7,9,13,13a-decahydropyrido[1?,2?:4,5]pyrazino[1,2-a]pyrrolo[1,2-c]pyrimidines having the anti-virus activity, particularly the HIV integrase inhibitory activity, and a pharmaceutical composition containing the same, particularly an anti-HIV pharmaceutical composition.
    Type: Application
    Filed: January 27, 2022
    Publication date: July 7, 2022
    Applicants: Shionogi & Co., Ltd., ViiV Healthcare Company
    Inventors: Brian A. JOHNS, Takashi KAWASUJI, Teruhiko TAISHI, Yoshiyuki TAODA
  • Publication number: 20220119417
    Abstract: The invention relates to compounds of Formula (I), (Ia), (Ib), (II) or (III), salts thereof, pharmaceutical compositions thereof, as well as therapeutic methods of treatment and prevention.
    Type: Application
    Filed: August 6, 2021
    Publication date: April 21, 2022
    Applicants: GlaxoSmithKline Intellectual Property Development Limited, The University of North Carolina at Chapel Hill, ViiV Healthcare Company
    Inventors: Martha DE LA ROSA, Richard M. DUNHAM, David MARGOLIS, Vincent Wing-Fai TAI, Jun TANG
  • Publication number: 20220117993
    Abstract: The invention relates to compounds of the Formula: salts thereof, pharmaceutical compositions thereof, combinations thereof, as well as therapeutic methods of treatment and prevention.
    Type: Application
    Filed: August 8, 2019
    Publication date: April 21, 2022
    Applicants: GlaxoSmithKline Intellectual Property (No. 2) Limited, VIIV Healthcare Company
    Inventors: John Franklin MILLER, David TEMELKOFF, Emile Johann VELTHUISEN, Martha Alicia DE LA ROSA, Lita SUWANDI, B. Narasimhulu NAIDU
  • Publication number: 20220096487
    Abstract: Invented are methods for treating HIV in a human in need thereof which comprises the administration of a therapeutically effective amount of a combination of dolutegravir or a pharmaceutically acceptable salt thereof and lamivudine or a pharmaceutically acceptable salt thereof, to such human.
    Type: Application
    Filed: February 3, 2020
    Publication date: March 31, 2022
    Applicant: VIIV HEALTHCARE COMPANY
    Inventor: Martin John GARTLAND
  • Patent number: 11267823
    Abstract: Substituted 1,2,3,3a,4,5,7,9,13,13a-decahydropyrido[1?,2?:4,5]pyrazino[1,2-a]pyrrolo[1,2-c]pyrimidines having the anti-virus activity, particularly the HIV integrase inhibitory activity, and a pharmaceutical composition containing the same, particularly an anti-HIV pharmaceutical composition.
    Type: Grant
    Filed: July 9, 2020
    Date of Patent: March 8, 2022
    Assignees: SHIONOGI & CO., LTD., VIIV HEALTHCARE COMPANY
    Inventors: Brian A. Johns, Takashi Kawasuji, Teruhiko Taishi, Yoshiyuki Taoda
  • Patent number: 11224597
    Abstract: The present Invention relates to pharmaceutical compositions of (3S,11aR)—N-[(2,4-difluorophenyhmethyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide, useful in the treatment or prevention of Human Immunodeficiency Virus (HIV) infections.
    Type: Grant
    Filed: October 13, 2016
    Date of Patent: January 18, 2022
    Assignee: ViiV Healthcare Company
    Inventors: Deepak B. Mundhra, Rennan Pan
  • Publication number: 20210323993
    Abstract: The invention relates to compounds of Formulae (I), (Ia), (II) and (IIa), salts thereof, pharmaceutical compositions thereof, as well as methods of treating or preventing HIV in subjects.
    Type: Application
    Filed: August 28, 2019
    Publication date: October 21, 2021
    Applicants: GlaxosmithKline Intellectual Property (No. 2) Limited, ViiV Healthcare Company
    Inventors: John MILLER, David TEMELKOFF, Emile Johann VELTHUISEN, Martha Alicia DE LA ROSA, Lisa SUWANDI
  • Patent number: 11117904
    Abstract: The present invention provides compositions and methods for the delivery of antivirals to a cell or subject.
    Type: Grant
    Filed: June 22, 2017
    Date of Patent: September 14, 2021
    Assignees: ViiV Healthcare Company, Board of Regents of University of Nebraska
    Inventors: Benson J. Edagwa, Howard E. Gendelman, Brian Alvin Johns
  • Patent number: 10927129
    Abstract: The present invention is directed to N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide of the formula: or a pharmaceutically acceptable salt or stereoisomer thereof, and pharmaceutical compositions comprising the same. The present invention has HIV integrase inhibitory activity.
    Type: Grant
    Filed: May 1, 2019
    Date of Patent: February 23, 2021
    Assignees: SHINOGI & CO., LTD., VIIV HEALTHCARE COMPANY
    Inventors: Brian A. Johns, Takashi Kawasuji, Teruhiko Taishi, Yoshiyuki Taoda
  • Publication number: 20210009609
    Abstract: The invention relates to compounds of Formula (I), salts thereof, combinations, pharmaceutical compositions thereof, as well as therapeutic methods of treatment and prevention.
    Type: Application
    Filed: October 5, 2020
    Publication date: January 14, 2021
    Applicants: GlaxoSmithKline Intellectual Property Development Limited, The University of North Carolina at Chapel Hill, ViiV Healthcare Company
    Inventors: Martha DE LA ROSA, Richard M. DUNHAM, David MARGOLIS, Vincent Wing-Fai TAI, Jun TANG